Quick Answer
BIOLARGO, INC. reported R&D Expense of $2.59 million for fiscal year 2025.
BIOLARGO, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.59M | -10.0% |
| 2024 | $2.88M | +26.3% |
| 2023 | $2.28M | +73.0% |
| 2022 | $1.32M | -3.5% |
| 2021 | $1.37M | +2.2% |
| 2020 | $1.34M | -9.1% |
| 2019 | $1.47M | -14.4% |
| 2018 | $1.72M | +5.5% |
| 2017 | $1.63M | +17.9% |
| 2016 | $1.38M | +101.9% |
| 2015 | $684.6K | +6.5% |
| 2014 | $642.9K | -13.4% |
| 2013 | $742.2K | +93.5% |
| 2012 | $383.5K | +285.5% |
| 2011 | $99.5K | -1.1% |
| 2010 | $100.6K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $615.0K | -10.9% | +15.0% |
| June 30, 2025 | $535.0K | -14.1% | -32.4% |
| March 31, 2025 | $791.0K | +0.9% | +14.6% |
| September 30, 2024 | $690.0K | -0.6% | +10.8% |
| June 30, 2024 | $623.0K | +6.1% | -20.5% |
| March 31, 2024 | $784.0K | +38.8% | +13.0% |
| September 30, 2023 | $694.0K | +156.1% | +18.2% |
| June 30, 2023 | $587.0K | +65.4% | +3.9% |
- BIOLARGO, INC. showed a decrease of -10.0% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, BIOLARGO, INC.’s r&d expense has grown by 2478.5% (from $100.6 thousand to $2.59 million).
- The most recent figure is from BIOLARGO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: